Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

By Joseph Tulloch For years, AI safety experts have been warning of a future moment where AI models become advanced enough to ...

An agent can produce a mathematically elegant, third-normal-form schema that is functionally irrelevant because it fails to capture the political or operational nuances of the organization. Deploying ...

"If you love trains, you understand the big difference between knowing a train is due soon and actually seeing the massive ...

Citadel Securities challenges Citrini Research's dystopian economic crisis forecast of AI destroying global jobs, leading to a market crash and record unemployment in 2028.

What's CODE SWITCH? It's the fearless conversations about race that you've been waiting for. Hosted by journalists of color, our podcast tackles the subject of race with empathy and humor. We explore ...

AI development is often framed as a race among countries, companies and academic researchers. But figuring out who’s actually ...

From the "Ghost GDP" to mass layoffs at tech companies, this was the week AI's new collar economy took full effect.

Discover the top 5 advanced AI technologies, from voice-first interfaces to proactive healthcare and cognitive offloading, ...

As artificial intelligence accelerates into every corner of business, science, and society, the leaders steering its cou ...

If you’ve used Linux for a long time, you know that we are spoiled these days. Getting a new piece of hardware back in the day was often a horrible affair, requiring custom kernels and lots ...